Background-Amputation rates and mortality in patients with severe acute limb ischemia remain high. The protective effect of controlled reperfusion (CR) on tissue damage because of local and systemic reperfusion injury is unclear. Methods and Results-A total of 174 patients from 14 centers were randomized between conventional treatment (CT) by thrombembolectomy and normal blood reperfusion and thrombembolectomy followed by CR. The primary end point was amputation-free survival (AFS) after 4 weeks (CT, 82.4%; CR, 82.6%). Secondary end points were AFS (CT, 62.4%; CR, 63.1%) and overall survival (CT, 71.6%; CR, 76.3%) after 1 year. Analysis of the prognostic effects of preoperative factors revealed a strong adverse effect of bilateral involvement on AFS. In the subgroup with unilateral ischemia (n=160), age >80 years and central localization of the occlusion had independent negative prognostic effects on AFS. In the perprotocol population of 104 patients with unilateral ischemia, treatment per protocol, and successful revascularization, amputation or death within 4 weeks occurred in only 8% as compared with 33% in patients not fulfilling these criteria.
A cute limb ischemia (ALI) because of arterial thrombosis or embolism is a frequent emergency in developed countries and remains a challenge even to state-of-the-art vascular surgery. Amputation rates of ≈10% to 15% and mortality of up to 25% within 1 year after the event have not changed in the past decades, despite the development of advanced therapies like thrombolysis and endovascular techniques. [1] [2] [3] The ischemic tolerance of skeletal muscle is ≈4 hours. 4 Although revascularization is the condition sine qua non for salvage of the ischemic limb, it leads to a local and even systemic reperfusion injury. The concept of controlled reperfusion (CR) was introduced in the 1980s to ameliorate this subsequent damage. 5, 6 The efficacy in experimental hindlimb ischemia was proven by Beyersdorf et al. 7 It has found widespread acceptance, especially in cardiac surgery. 8 CR consists of 2 components: controlling the conditions of reperfusion with regard to flow, pressure, and duration, and controlling the reperfused fluid. Specific reperfusates were designed to limit the damage by reactive oxidative species and to restore cellular energy and substrate metabolism. 9, 10 First results of clinical application of CR in patients with severe acute lower-limb ischemia have been published previously. 11, 12 To prove the promising findings, a randomized prospective controlled trial on Controlled Reperfusion of the Acutely Ischemic Limb (CRAIL trial) was initiated. In this multicenter study, conventional surgical thrombembolectomy was compared with recanalization with CR.
Methods

Study Design
The CRAIL trial was designed as a prospective, randomized, openlabel, multicenter superiority trial to compare efficacy and safety of conventional treatment (CT) using thrombembolectomy with normal blood reperfusion to thrombembolectomy with additional CR in patients with acute ischemia of a lower limb.
The study was approved by the ethics committee of the Albert-Ludwigs-University Freiburg, Germany, and the responsible local ethics committees of the participating centers. Each patient provided written informed consent. The trial is registered with World Health Organization primary register. For participating centers, see onlineonly Data Supplement I.
Adult patients (aged ≥18 years) with acute arterial occlusion of one or both legs and uncompensated ischemia (Rutherford classification of ALI, stages IIA-III) 13 were eligible for the study. Exclusion criteria were preceding attempts of revascularization (eg, lysis, percutaneous procedures), known aneurysm of the popliteal artery, New York Heart Association IV, decompensated renal insufficiency, intolerance of the reperfusion components, participation in another clinical trial, pregnancy, breast feeding, and substance, drug, or alcohol abuse.
Surgical Techniques
Conventional revascularization was done according to standards. 14 The common, superficial, and deep femoral arteries are exposed through a standard groin incision, and thrombembolectomy is performed using a balloon catheter. Thereafter, normal blood reperfusion was allowed. No additional thrombolysis using drug was applied.
The technique of CR used in this study has been described previously. 12 The perfusion set for applying controlled limb reperfusion consists of 2 blood bags (each capable of holding 1 L), crystalloid solution, a blood line, and a reperfusion line (0.25-inch polyester tubes). The crystalloid reperfusion solution (Dr Franz Köhler Chemie, Bensheim, Germany; online-only Data Supplement II) consists of 2 separate formulations which are mixed immediately before use and supplemented with Allopurinol (A/S GEA, Fredriksburg, Denmark).
After standard thrombembolectomy and before restoration of blood flow, a 10-Charrier cannula is inserted proximally into the iliac artery, another 10-Charrier cannula is inserted distally into the femoral artery through the same incision, and whenever possible, a third cannula is inserted into the deep femoral artery. The proximal cannula is connected to the blood line, and oxygenated blood is drawn into the first blood bag where it is mixed with the crystalloid reperfusion solution at a ratio of 6:1. Three hundred or 600 mL of blood is taken at every cycle. After the blood-reperfusion solution has been transferred to the second blood bag, the reperfusion line is connected to this second blood bag. After deairing of the reperfusion line, CR is initiated via the distal cannula. A 12-gauge cannula is inserted into the femoral artery distal of the reperfusion cannula for continuous pressure control to maintain a maximal perfusion pressure of 60 mm Hg. In most cases, the blood-reperfusion solution is returned to the leg by gravity alone. Perfusion pressure is varied by changing the height of the blood bag. If necessary, a pressure-cuffed bag is put around the reperfusion bag. The procedure is repeated for 30±3 minutes. After removal of the cannulas, the arteriotomy is closed with direct suture or patch reconstruction, and normal blood flow is re-established.
Revascularization was considered successful when the balloon catheter was inserted >60 cm and adequate backbleeding occurred, or when there was a strong Doppler signal at the A. tibialis posterior or A. dorsalis pedis postoperatively, or when these arteries appeared normal or only slightly stenosed in a postoperative angiography.
The cause of the occlusion, embolus or thrombus, was documented by the surgeon according to the intraoperative clinical picture.
A range of laboratory data (creatinine kinase, lactate dehydrogenase, glutamate oxalacetate transaminase, glutamate pyruvate transaminase, creatinine, and c-reactive protein) were analyzed preoperatively and 12 hours, 72 hours, and 4 weeks postoperatively. Data were classified normal, abnormal without clinical relevance, and abnormal with clinical relevance because of input from the laboratories of the various centers with differing methods and references.
Data Management and Quality Control
Data of patients were documented on study-specific case report forms. Data management was performed centrally by an independent clinical trial center where data were checked for completeness and plausibility. Independent clinical monitoring was done regularly in the clinical centers, where random samples of the data recorded in the case report forms were verified by inspection of the source data in the patients' charts.
Follow-up and End Points
Intensive follow-up of the patients was conducted until 4 weeks after surgery. After 6 and 12 months, patients or relatives were contacted by phone for recording patient's amputation and survival status. Toe amputation was not counted as amputation. Because there were only 2 toe amputations in the CT group and 1 toe amputation in the CR group, counting toe amputations would not have changed the result.
The primary efficacy end point was the combined end point amputation-free survival (AFS) 4 weeks after surgery. Secondary efficacy end points were amputation and death within 1 year after surgery. Specifically, the following end points were analyzed: AFS time, time to amputation, and time to death without former amputation, both considering the opposite event as competing, overall survival time, time to cardiac death, and time to noncardiac death, both considering the opposite event as competing, and time to amputation or cardiac death, considering noncardiac death without former amputation as competing event. For patients who did not experience the respective events of interest, the time from surgery to the last follow-up was used as censored observation.
Another secondary end point was safety. Adverse events (AEs) and serious AEs (SAEs) were documented until 4 weeks after surgery and coded by means of the Medical Dictionary for Regulatory Activities, version 11.0.
Statistical Procedures
Randomization
The randomization code was produced by the clinical trials center using a computerized random-number generator. Randomization was stratified by center, thus guaranteeing that treatments were balanced within centers. A 1:1 block randomization with randomly varying block size was performed using sealed and opaque envelopes with consecutive patient numbers to be opened in a given order indicating the randomized treatment (CT, CR). Adherence to the procedure was verified by clinical monitors, ensuring concealment of the randomized treatment.
Sample-Size Calculation
Sample-size calculation was based on the primary end point AFS 4 weeks after surgery. It was assumed that the AFS rate is ≈70% after CT. [15] [16] [17] To detect a difference of 70% versus 85% between treatment groups with 80% power using a 2-sided χ 2 test at level
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α=0.05, the required total number of patients was calculated as 238. To account for 2 planned interim analyses, 250 patients were planned to be randomized.
Interim Analyses
Two formal interim analyses for efficacy were planned, based on 4-week data of the first 80 patients and of the first 160 patients. To control the type I error rate, a sequential test procedure was used with an α-spending function of the O'Brien-Fleming type. 18 This resulted in a preplanned significance level of α=0.0005 for the first, α=0.014 for the second interim analysis, and a level of α=0.045 for the final analysis. During the second interim analysis, a conditional power analysis was performed because of the slow study recruitment rate. The probability to detect a significant difference between treatment groups after study completion with 250 patients was calculated conditional on the results of the first 160 patients included in the interim analysis and assuming that the current trend continues in the remaining 90 patients. The conditional power was calculated according to Lan and Wittes, 19 and additionally using simulation. This resulted in a probability of ≈3% for a significant difference in any direction. The results of the interim analysis were available only to the Data Monitoring Committee.
Analysis Sets
The primary efficacy analysis was performed in the full analysis set (FAS). The FAS included all randomized patients who underwent surgery and for whom at least baseline documentation was available, irrespective of whether the treatment had followed the protocol. Patients were analyzed as belonging to the randomized treatment arm according to intention-to-treat.
As a sensitivity analysis, an efficacy analysis was done in the per-protocol population, defined as a subset of patients, for whom the maximal benefit of CR would have been expected. This included only patients with unilateral ischemia who fulfilled the inclusion and exclusion criteria, received CT or CR according to protocol (duration of CR ≥27 minutes), and for whom successful revascularization was achieved. In the perprotocol population, patients were analyzed according to their received treatment.
Safety analyses were performed in the safety population. This includes all patients of the FAS, but patients were analyzed according to treatment received. Figure 1 . Patient flow. The safety population is defined by treatment received: 1 CT (n=92); 2 CR (n=79). CR indicates controlled reperfusion; CT, conventional treatment; and FAS, full analysis set according to randomization. August 2013
follow-up regarding amputation/death until 12 months visit
Comparison of Treatment Groups
The comparison of the treatment groups with respect to the primary end point was done using a logistic regression model being stratified for center (centers with ≤5 patients combined in 1 group), thus adjusting for differences among centers. As an estimate of effect size, the odds ratio of CR versus CT was calculated with 95% confidence interval (CI).
To compare the treatment groups with respect to time-toevent variables, for which no competing events had to be considered, that is, AFS time, overall survival time, time to amputation, and cardiac death, the probability of event over time was estimated by the Kaplan-Meier method, and the time to event was compared between the treatment groups with Cox regression models, using 2-sided Wald tests. When comparing the treatment groups with respect to time-to-event variables, for which competing events had to be considered, that is, time to amputation, time to death without amputation, time to cardiac death, and time to noncardiac death, the probability of event over time was estimated by cumulative incidence rates, 20 and the time to event was compared between the treatment groups with Cox regression models for the event-specific hazard functions using 2-sided Wald tests. As an estimate of effect size, the hazard ratios of CR versus CT were calculated with 95% CI in the Cox regression models. As exploratory analyses, the interactive effects between treatment and several pre-and intraoperative prognostic factors on the end points, AFS time, time to amputation, overall survival time, and cardiac death, were analyzed in the FAS with Cox regression models, including the multiplicative interaction between treatment and prognostic factor. The treatment effects within prognostic subgroups were estimated with 95% CI.
The incidences of AEs and SAEs were calculated as the number of patients who experienced ≥1 AE of a certain category defined by MedDRA System Organ Classes and MedDRA Preferred Terms as a percentage of the total number of patients in the safety population.
Analysis of Prognostic Factors
The effect of prognostic factors on AFS time, time to amputation, and overall survival time were analyzed with adjustment for treatment received. The effect of the extent of the ischemia (unilateral versus bilateral) was evaluated in the FAS. Analysis of the effect of other prognostic factors was then restricted to patients with unilateral ischemia for reasons of homogeneity and because there were only 11 patients with bilateral ischemia. First, univariate analyses of the effect of the preoperative factors (age, sex, anticoagulant medication, duration of ischemia, Rutherford stage, and extent of vascular obliteration) were performed. Factors with a P value of ≤0.05 were then included in a multivariate analysis. The effect of revascularization was analyzed with and without adjustment for those preoperative factors showing an effect in the multivariate analysis with P≤0.05.
Results
Patient Characteristics
Between October 2002 and March 2008, 14 centers in Germany and Austria recruited 174 patients for the CRAIL study (86 CT, 88 CR). The conditional power calculation performed in the second interim analysis resulted in a probability of ≈3% for a significant difference between treatment groups after study completion with 250 patients conditional on the results of the first 160 patients included in the interim analysis. Therefore, the Data Monitoring Committee recommended stopping of the study after the second interim analysis based on 160 patients. Because patient recruitment was not suspended during the interim analysis, 14 additional patients were recruited before recruitment of patients into the study was finally stopped. A median number of 4 patients were treated per center (range, 2-66). Five centers recruited >5 patients each.
Patient flow is shown in Figure 1 . Three patients had to be excluded from the FAS, resulting in 171 patients in the FAS (85 CT, 86 CR). Regardless of the outcomes of the 3 excluded patients, the results would have been virtually unchanged. Two of the patients randomized to CT received CR. Nine patients randomized to CR did not receive CR. As a result, the safety population consisted of 92 CT and 79 CR patients (Figure 1) .
The primary end point was obtained for all patients. Oneyear follow-up was incomplete for 4 patients (1 CT, 3 CR).
Baseline data and distribution of pre-existing conditions are given in Table 1 . A total of 58% of all patients were ≥70 years, 60% were men, 30% experienced heart failure, and 27% had diabetes mellitus. A peripheral arterial disease had been diagnosed previously in 52%. Ten patients (7 CT, 3 CR) had undergone an amputation before the current arterial occlusion. A total of 53% of the patients took anticoagulant drugs at admission, 29% presented with total ventricular arrhythmia or atrial fibrillation at admission. Table 2 shows the characteristics of ischemic events. Ischemia lasted for >6 hours in 81% of the patients, in 27% for >24 hours, and in 3% for >1 week. A total of 88% had Rutherford stage IIB or III, and the occlusion was located at or above the femoral bifurcation in 63%. Vascular obliteration occurred because of arterial embolism in 56% of the patients. Eleven patients presented with bilateral acute ischemia as determined by clinical findings.
Successful revascularization was achieved in 68% of the patients. The success of revascularization did not correspond to the type of treatment (CR: 66% versus CT: 69%; odds ratio, 0.87; 95% CI, 0.46-1.65; P=0.66). The per-protocol population consisted of 104 patients (59 CT, 45 CR) with unilateral acute ischemia and treatment per protocol with successful revascularization. Table 3 shows the results of the primary end point of AFS 4 weeks after surgery. Fifteen patients in each treatment group were amputated or died within the first month. Eleven patients with CT and 10 with CR died within 4 weeks, 8 patients each from a cardiovascular cause. The type of treatment had no effect on primary outcome in the FAS. Creatinine kinase, lactate dehydrogenase, glutamate oxalacetate transaminase, glutamate pyruvate transaminase, creatinine, and c-reactive protein were analyzed preoperatively and 12 hours, 72 hours, and 4 weeks postoperatively. No significant changes were detected between the treatment groups.
Comparison of Treatments
In the per-protocol population with unilateral ischemia, treatment per protocol, and successful revascularization, rates of amputation and death were reduced (Table 3) . Only 8% (8/104) of this population experienced an amputation or death within 4 weeks as compared with 33% (22/67) of patients not fulfilling these criteria. Even if we limit the analysis to this population who had treatment according to protocol, there was no benefit for the CR group (amputation or death within 4 weeks 6.7%) as compared with the CT group (amputation or death within 4 weeks 8.5%; P=0.75). Death of all 6 deceased patients occurred because of cardiovascular events.
Within 1 year, 30 patients experienced an amputation and 44 patients died (33 without an amputation and 11 after an amputation). A total of 62.6% of the 171 patients were alive and without amputation (CR 63.1% versus CT 62.1%). The treatment had no effect on the rates of amputation or death or on the causes of death ( Figure 2 ; Table 4 ), neither in the FAS nor in the per-protocol population of patients with unilateral ischemia, treatment per protocol, and successful revascularization.
To examine whether a treatment effect was present in patients subgroups defined by various pre-and intraoperative conditions, the interactive effects were analyzed in the FAS. Figure 3 illustrates the estimated treatment effects on AFS time within subgroups. No patient subgroup with different AFS rates in the treatment groups could be identified. The same analyses with regard to time to amputation and overall survival time, and time to amputation or cardiac death also did not disclose any differences (not shown).
In the safety population, 49 patients (53.3%) in treatment group CT (n=92) and 41 patients (51.9%) in treatment group CR (n=79) experienced ≥1 AE. At least 1 SAE occurred in 24 patients (26.1%) in treatment group CT and in 20 patients (25.3%) in treatment group CR. Online-only Data Supplement III shows the incidence of SAEs by system organ class and by treatment group. There was no difference between the 2 groups.
Because treatment assignment in the safety population was influenced by selection criteria, the analysis of AEs was additionally performed in the FAS as sensitivity analysis. In the FAS, 41 patients (48.2%) in treatment group CT (n=85) and 49 patients (57.0%) in treatment group CR (n=86) experienced ≥1 AE. At least 1 SAE occurred in 21 patients (24.7%) in treatment group CT and in 23 patients (26.7%) in treatment group CR. Online-only Data Supplement IV shows the incidence of SAEs by system organ class and by treatment group. There was no difference between the 2 groups.
In addition, the treatment comparison of CT versus CR with respect to AFS time was performed separately in 66 patients treated in the largest center and in 105 patients treated in the other 13 centers. In both subgroups, no significant difference between CT and CR was present (largest center, P=0.45; other centers, P=0.44), and the test for interaction between the factors center (largest, other) and treatment (CT, CR) resulted in a P value of 0.28. This indicates that no differences between treatment effects (CT versus CR) in the centers (largest versus other) could be detected.
Effects of Prognostic Factors
The extent of ischemia had a strong effect on AFS with a 1-year rate of 65.7% in patients with unilateral ischemia and of 27.3% in patients with bilateral ischemia (hazard ratio, 3.16; 95% CI, 1.50-6.66; P=0.002). The same effect was observed for amputation with a 1-year rate of 15.4% for unilateral and 45.5% for bilateral ischemia (hazard ratio, 4.26; 95% CI, 1.63-11.2; P=0.003). Table 5 shows the effects of preoperative factors on AFS time in 160 patients with unilateral disease. Age >80 years and central localization of the occlusion had independent adverse effects on AFS (55 events). Intraoperative successful revascularization reduced the risks for amputation and death, also after adjustment for age and extent of obliteration (hazard ratio, 0.49; 95% CI, 0.28-0.84; P=0.010). No effects of any preoperative factors on amputation alone were found, but the power to detect a difference is low with just 25 events.
Discussion
Summary of Results
CR of ischemic tissue aims at prevention of an ischemiareperfusion injury. Here, we present the first randomized controlled multicenter trial on the effect of CR in patients with acute arterial occlusion of the leg. CR subsequent to surgical removal of the arterial thrombus or embolus consisted of application of a crystalline solution mixed with blood at a maximal perfusion pressure of 60 mm Hg. Eighty-six patients randomized to CR were compared with 85 patients randomized to CT. AFS after 4 weeks was 82%. After 1 year, 63% of the patients were alive and not amputated. No difference between the 2 treatment groups could be identified, neither overall nor in patient subgroups defined by various pre-and intraoperative conditions. The sensitivity analysis in the per-protocol population included 104 patients who had unilateral occlusion, were treated per protocol and revascularized successfully. In this group, the combined risk of amputation or death within 4 weeks was reduced to 8% compared with 33% in the group of patients not fulfilling these criteria. But even if we limit the analysis to this population who had treatment according to protocol, there was no benefit for the CR group as compared with the CT group.
In the overall study population, extent of ischemia had a strong effect on the risk of amputation. In patients with unilateral ischemia, age and localization of the vascular occlusion were independent prognostic factors for AFS.
Comparisons With Other Studies
The overall short-term mortality of patients with ALI is reported to be 15% to 20%. 14 There are several articles on outcome of open revascularization in ALI from the 1980s and 1990s, preceding the wide-spread implementation of percutaneous techniques. They were followed by publications on randomized trials comparing surgical measures to catheter-directed thrombolysis with varying assignment algorithms, end points, and results. 21 Mortality in the surgical arms of these studies ranged from 7% to 37% after 30 days. 1, 16 The calculation of the sample size in our trial was based on Burgess et al, 15 Earnshaw et al, 16 and Ljungman et al. 17 These studies reported amputation rates of 6% to 15% and mortality of 37% to 45% within 30 days, and ≈20% to 30% amputation rates and ≈50% survival after 1 year after CT, respectively. Since the late 1990s, percutaneous interventions have developed to standard procedures for a part of patients with ALI. Currently they are recommended for viable and marginally treated limbs (Rutherford I and IIa) . Surgical treatment is left for immediately threatened or extensively damaged limbs (Rutherford IIb and III). 13, 14 However, within 4 weeks, only 13% of patients in our CT group died and 5% were amputated but alive. After 1 year, 72% of patients in the CT group were alive.
Acute arterial occlusion of a limb represents one symptom of advanced systemic cardiovascular disease which limits survival. 14 Patients who need open revascularization have a significantly higher frequency of cardiovascular, including metabolic, comorbidities than patients who are amenable to endovascular treatment. 22 This finding supports the observation made in our and in other studies 23 that most patients die from cardiovascular causes, both in the first month and in the follow-up period.
Role of CR
Irreversible tissue damage in ALI is caused, on the one hand, by the ischemia itself. Percutaneous or surgical revascularization is indispensable to rescue the affected limb. The reperfusion results, on the other hand, in an ischemia-reperfusion injury. Ischemia-reperfusion injury leads to release of reactive oxygen species, activation of endothelial cells and leukocytes, expression of proinflammatory cytokines by various types of cells, and immigration of macrophages and granulocytes, and results in capillary no-reflow, interstitial edema, and cellular destruction. [24] [25] [26] The dreaded local and systemic clinical effects include compartment syndrome and cardiogenic shock, respectively.
The reperfusion solution used in our study was developed according to experiences with reperfusion of the heart in cardiac surgery.
Glucose serves as metabolic substrates for starving endothelial and muscle cells to restore depleted ATP. Moreover, glutamate and aspartate contribute to restitution of cellular metabolism. 27, 28 Furthermore, glutamate is a precursor of glutathione. 29 This antioxidant contributes to protection from damage from reactive oxygen species by induction of heat shock responses which, in turn, attenuate proinflammatory cytokine release. 30 The break-down of metabolism during ischemia leads to cellular acidosis. Maintenance or restoration of an optimal intracellular pH is necessary to ensure optimal functioning of metabolic enzymes and contractile elements. 31 Therefore, the reperfusion solution contains trometamol and dihydrogen phosphate as buffering substances.
Allopurinol was used as a radical scavenger. It has been suggested that allopurinol can block, at least in part, damage to the endothelial cells in reperfused skeletal muscle hereby attenuating the compartment syndrome caused by oxygenfree radicals. 32 Citrate serves as a calcium chelator. The role of calcium has been scrutinized in myocardium. 33 Reperfusion injury leads to intracellular redistribution which is associated with irreversible damage of mitochondria and cellular membranes. 34 Of note, aged myocardium has been shown to accumulate [Ca] 2+ in a higher degree during ischemia and exhibit less functional recovery at reperfusion than juvenile hearts. 35 However, no patient subgroup defined by prognostic factors could be identified that had a significant advantage from CR in this situation of most severe ALI. Although AFS after 4 weeks was lower in the CR group (event rate 6.7% compared with 8.5% with CT), it did not reach statistical significance. It is possible that the conditions of the patients leveled out the beneficial potential of this surgical adjunct. Further possible reasons are discussed in Limitations.
Prognostic Factors
An analysis of comorbidities in patients with open revascularization procedures, without regard to acute or chronic obliteration, found a significant increase of hypertension, coronary artery, chronic obstructive pulmonary and renal diseases between 1998 and 2007. 3 Furthermore, a trend to a higher frequency of emergency procedures was observed. 36 We have the impression of similar tendencies in our patient population, although we did not analyze the corresponding long-term data. According to several previous studies, higher age is associated with higher mortality and amputation rates. 37, 38 Although patients at age ≥90 years undergoing vascular procedures have "reasonable early outcomes" in general, ALI results in a mortality of 40% to 50% in this population. 39 In our study, patients who were ≥80 years had an almost doubled risk for amputation and death compared with patient who were <70 years. The other variable we found to be a predictor for outcome was the localization of the vascular obliteration which defines the extent of the ischemic area. This is in line with several other investigations. 38, 40, 41 Limitations • The study design aimed at ALI. However, the actual duration of ischemia had to be estimated in some patients.
• We observed a high number of protocol violations especially in the treatment arm. More intensive and repeated training of the participating surgeons would have been necessary.
• The blood flow during reperfusion was not controlled. We relied only on established surgical techniques for verification of successful reperfusion. Quantification of the flow using an ultrasonic probe would have given additional information.
• Furthermore, the optimal reperfusion conditions with regard to pressure, flow, and composition of the reperfusate are still unknown.
Conclusions
In this randomized clinical study on surgical reperfusion of the acutely ischemic leg, we found similar AFS in patients with conventional thrombembolectomy or with CR. As discussed above, our results with regard to AFS were better than expected from previously published studies also in the CT group. It seems possible that a meticulous surgical technique and the setting of a clinical trial, especially for these emergency patients, leaves not much room for further improving the outcome by CR. Further investigations on the mechanisms of local and systemic reperfusion injury are necessary to achieve a better outcome of these severely ill patients.
